Table 4. Multivariable Cox Proportional Hazards Model for Relapse Free Survival (RFS) and Overall Survival (OS) relative to total cMET and phospho-cMET expression.

	cMET							p-cMET
	RFS			OS				RFS			OS
Model	HR	95% CI	P	HR	95% CI	P	Model	HR	95% CI	P	HR	95% CI	P
cMET: High vs. Low	2.06	1.08-3.94	0.028	2.81	1.19-6.64	0.019	p-cMET: High vs. Low	1.79	1.08-2.95	0.020	1.84	0.97-3.48	0.062
Subtype: HER2+ vs. HR+	1.03	0.54-1.98	0.925	1.24	0.53-2.90	0.621	Subtype: HER2+ vs. HR+	1.00	0.52-1.92	0.999	1.11	0.48-2.60	0.803
Subtype: TN vs. HR+	0.65	0.34-1.25	0.201	2.00	0.87-4.58	0.103	Subtype: TN vs. HR+	0.59	0.31-1.14	0.115	1.62	0.71-3.73	0.249
Age: >50 vs. ≤50	0.79	0.48-1.28	0.339	0.97	0.53-1.77	0.924	Age: >50 vs. ≤50	0.83	0.51-1.34	0.441	1.06	0.58-1.93	0.848
Chemotherapy: A vs. N	0.06	0.01-0.25	0.0001	0.20	0.03-1.07	0.061	Chemotherapy: A vs. N	0.05	0.01-0.23	0.0001	0.15	0.03-0.78	0.024
Chemotherapy: T vs. N	0.13	0.05-0.33	<0.0001	0.26	0.08-0.82	0.025	Chemotherapy: T vs. N	0.13	0.53-0.34	<0.0001	0.28	0.08-0.89	0.032
Chemotherapy: B vs. N	0.10	0.05-0.18	<0.0001	0.28	0.13-0.63	0.002	Chemotherapy: B vs. N	0.10	0.56-0.19	<0.0001	0.26	0.13-0.54	0.0003
Hormonal Therapy: Y vs. N	0.21	0.10-0.43	0.0001	0.31	0.11-0.84	0.022	Hormonal Therapy: Y vs. N	0.16	0.08-0.33	<0.0001	0.23	0.08-0.63	0.004
Radiation Therapy: Y vs. N	0.91	0.53-1.56	0.740	0.80	0.41-1.57	0.523	Radiation Therapy: Y vs. N	0.84	0.49-1.45	0.528	0.81	0.41-1.59	0.545
Grade: I, II vs. III	0.84	0.48-1.50	0.419	0.72	0.33-1.53	0.390	Grade: I, II vs. III	0.94	0.52-1.67	0.819	0.77	0.36-1.68	0.514
Clinical Stage: I, II vs. III	0.37	0.22-0.62	0.0002	0.67	0.33-1.34	0.243	Clinical Stage: I, II vs. III	0.40	0.24-0.69	0.0009	0.77	0.38-1.55	0.458

RFS: Relapse Free Survival, OS: Overall Survival, cMET: total cMET, p-cMET: phospho-cMET, HR: Hazard ratio, HR+: Hormone receptor positive, TN: Triple Negative, A: Anthracycline based, B: Both Anthracycline & Taxane, T: Taxane based